293 related articles for article (PubMed ID: 19965844)
1. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease.
Kang HS; Kim JH; Phi JH; Kim YY; Kim JE; Wang KC; Cho BK; Kim SK
J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):673-8. PubMed ID: 19965844
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H
Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633
[TBL] [Abstract][Full Text] [Related]
3. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
4. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
Lin SY; Wang YY; Sheu WH
Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636
[TBL] [Abstract][Full Text] [Related]
5. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
6. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis.
Jain A; Nanchahal J; Troeberg L; Green P; Brennan F
Arthritis Rheum; 2001 Aug; 44(8):1754-60. PubMed ID: 11508425
[TBL] [Abstract][Full Text] [Related]
7. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases and proangiogenic factors in testicular germ cell tumors.
Diamantopoulos N; Boutis AL; Koratzis I; Andreadis C; Galaktidou G; Mouratidou D; Kortsaris A
J BUON; 2010; 15(1):116-21. PubMed ID: 20414937
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.
Distler O; Del Rosso A; Giacomelli R; Cipriani P; Conforti ML; Guiducci S; Gay RE; Michel BA; Brühlmann P; Müller-Ladner U; Gay S; Matucci-Cerinic M
Arthritis Res; 2002; 4(6):R11. PubMed ID: 12453314
[TBL] [Abstract][Full Text] [Related]
10. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
11. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases.
Kim MH
J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886
[TBL] [Abstract][Full Text] [Related]
12. Platelet-rich plasma increases matrix metalloproteinases in cultures of human synovial fibroblasts.
Browning SR; Weiser AM; Woolf N; Golish SR; SanGiovanni TP; Scuderi GJ; Carballo C; Hanna LS
J Bone Joint Surg Am; 2012 Dec; 94(23):e1721-7. PubMed ID: 23224392
[TBL] [Abstract][Full Text] [Related]
13. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients.
Brattström D; Bergqvist M; Hesselius P; Larsson A; Lamberg K; Wernlund J; Brodin O; Wagenius G
Lung Cancer; 2002 Jul; 37(1):57-63. PubMed ID: 12057868
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518.
Crul M; Beerepoot LV; Stokvis E; Vermaat JS; Rosing H; Beijnen JH; Voest EE; Schellens JH
Cancer Chemother Pharmacol; 2002 Dec; 50(6):473-8. PubMed ID: 12451474
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
Eur Cytokine Netw; 2001; 12(3):445-52. PubMed ID: 11566625
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation.
Barron GA; Goua M; Wahle KWJ; Bermano G
Oncol Rep; 2017 Sep; 38(3):1886-1894. PubMed ID: 28714000
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165.
Hashimoto G; Inoki I; Fujii Y; Aoki T; Ikeda E; Okada Y
J Biol Chem; 2002 Sep; 277(39):36288-95. PubMed ID: 12114504
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
20. Cytokines, matrix metalloproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients.
Leonardi A; Sathe S; Bortolotti M; Beaton A; Sack R
Allergy; 2009 May; 64(5):710-7. PubMed ID: 19220217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
